GlaxoSmithKline Pakistan Limited reported a revenue of Rs 48.11 billion for the nine months ended September 30, 2026
Filed as: Financial Results for the Quarter Ended September 30, 2026
Summary
GlaxoSmithKline Pakistan Limited reported a revenue of Rs 48.11 billion for the nine months ended September 30, 2026, with a net profit of Rs 7.19 billion, reflecting a positive growth in both revenue and profit.
Read the original filingFigures in the filing
| Item | This period | Period before | Change |
|---|---|---|---|
| Revenue | PKR 48.11 billion | PKR 44.49 billion | +8.1% |
| Net Profit | PKR 7.19 billion | PKR 6.23 billion | +15.4% |
| Earnings Per Share | PKR 22.58 | PKR 19.57 | +15.4% |
| Operating Profit | PKR 12.12 billion | PKR 10.48 billion | +15.6% |
| Gross Profit | PKR 18.41 billion | PKR 15.92 billion | +15.7% |
Amounts are in Pakistani rupees as stated in the filing (M = million, B = billion).
What the filing says
- Revenue increased to Rs 48.11 billion from Rs 44.49 billion, a growth of 8.14% year-over-year.
- Net profit rose to Rs 7.19 billion from Rs 6.23 billion, marking a 15.41% increase.
- Earnings per share improved to Rs 22.58 from Rs 19.57, indicating a positive trend in profitability.
GlaxoSmithKline Pakistan Limited (GLAXO) on Nafa
Last price Rs 336.89 · Pharmaceuticals · You can own GLAXO shares from your phone.
More GLAXO announcements
Source: GlaxoSmithKline Pakistan Limited's filing with the Pakistan Stock Exchange. The summary and figures on this page are extracted from the filing by software and can contain errors; the filing itself is the record. This page describes the filing. It is not investment advice and Nafa does not recommend any stock. Investing in securities involves risk, including possible loss of principal.